INVITRIS
Live / Applied — Response to non-final action entered (as of 02 Sept 2026)
What this means for you
Not registered yet, but its 12 Oct 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99438872
- Mark type
- Stylized text
- Filed
- 12 Oct 2025
- Attorney of record
- Keith A. Weltsch
Goods and services
- Class 005 — Pharmaceuticals: Anti-microbial preparations for controlling biofilms and inhibition of bacteria; Anti- bacterial preparations, namely, sprays, creams and devices being containers for intravenous injection, namely, IV bags, infusion bottles, vials, ampoules, and prefilled syringes, sold filled with anti-bacterial pharmaceuticals; Anti-bacterial pharmaceuticals; Medicine for the prevention and treatment of infectious diseases being human or animal additives in the nature of dietary supplements for medical purposes; Food supplements for veterinary use; bacteriophages being pharmaceutical, medical, and veterinary preparations for prevention and treatment of bacteria-based diseases and disorders; Antibiotics; Anti-infectives; Preparations for microbiome health in the nature of probiotic preparations for medical use
- Class 040 — Treatment of materials: Custom biomanufacturing in the fields of pharmaceuticals, vaccines, diagnostics, industrial biotechnology, and agriculture, namely, custom biomanufacturing of proteins, nucleic acids, metabolites, and other biomolecules using cell-free biosynthesis systems to the order and specification of others; contract manufacturing in the field of cell-free biosynthesis; manufacturing process consulting services in the field of cell-free biosynthesis
- Class 042 — Scientific and technological services: Biomedical research services in the field of cell-free biosynthesis; research and development for the pharmaceutical industry in the field of cell-free biosynthesis; pharmaceutical research and development in the field of cell-free biosynthesis; biotechnology research in the field of cell-free biosynthesis; consultancy relating to pharmaceutical research and development in the field of cell-free biosynthesis; biological research, clinical research, and medical research in the field of cell-free biosynthesis; research and development in the pharmaceutical and biotechnology fields in the field of cell-free biosynthesis; clinical research in the field of cell-free biosynthesis; medical research in the field of cell-free biosynthesis; veterinary research in the field of cell-free biosynthesis; scientific research and development in the field of cell-free biosynthesis; bacteriological research in the field of cell-free biosynthesis; provision of scientific research services in the field of cell-free biosynthesis; scientific research and development services relating to bacteriophages in the field of cell-free biosynthesis; scientific research and development in the field of microbiomes in the field of cell-free biosynthesis; scientific research and development services relating to anti-infectives in the field of cell-free biosynthesis
Owner
- Invitris GmbH, Planegg-Martinsried, DE
Prosecution history
- 10 Sept 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 10 Sept 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 10 Sept 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 02 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Jun 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 04 Jun 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 04 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Mar 2026 — NON-FINAL ACTION E-MAILED
- 04 Mar 2026 — NON-FINAL ACTION WRITTEN
- 02 Mar 2026 — ASSIGNED TO EXAMINER
- 11 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Oct 2025 — APPLICATION FILING RECEIPT MAILED
- 12 Oct 2025 — NEW APPLICATION ENTERED